About Concordia International
Concordia International is a company based in Oakville (Canada) founded in 2016 by Mark Thompson. It operates as a B2B. The company has 264 employees as of March 31, 2023. Concordia International has completed 1 acquisition, including Amdipharm Mercury. Concordia International operates in a competitive market with competitors including Cardinal Health, CNX Therapeutics, Xiel, Bartec Technologies and SPL Pharma, among others.
- Headquarter Oakville, Canada
- Employees 264 as on 31 Mar, 2023
- Founders Mark Thompson
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Advanz Pharma Services (India) Private Limited
- Date of Incorporation 18 Jun, 1999
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$16.23 M (USD)20.56as on Mar 31, 2023
-
Net Profit
$1.83 M (USD)20.89as on Mar 31, 2023
-
EBITDA
$2.37 M (USD)38.94as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
264
as on Mar 31, 2023
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Concordia International
Detailed funding history for Concordia International
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Concordia International
Concordia International has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Amdipharm Mercury.
Investment portfolio details for Concordia International
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
A diversified portfolio of off-patent drugs is provided.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Concordia International
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Concordia International
Detailed financials for Concordia International
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Concordia International Comparisons
Peer comparison for Concordia International
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Concordia International
Concordia International operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cardinal Health, CNX Therapeutics, Xiel, Bartec Technologies and SPL Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Multiple healthcare products and services are provided to organizations.
|
|
| Locked | Locked | Locked |
Distributor of specialty drugs
|
|
| Locked | Locked | Locked |
Specialist nuclear medicine and radiotherapy solutions are distributed.
|
|
| Locked | Locked | Locked |
Mediso: Advanced medical imaging systems and radioactive sources
|
|
| Locked | Locked | Locked |
International distribution of specialty medicines and pharmaceutical market access services.
|
Detailed competitors of Concordia International
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Concordia International
Complete news archive for Concordia International
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Concordia International
Concordia International was founded in 2016.
Concordia International is headquartered in Oakville, Canada. It is registered at Oakville, Ontario, Canada.
Mark Thompson is the current CEO of Concordia International. They have also founded this company.
As of Mar 31, 2023, the latest employee count at Concordia International is 264.
Annual revenue of Concordia International is $16.23M as on Mar 31, 2023.
Concordia International distributes specialty pharmaceutical drugs to healthcare providers through providing healthcare solutions, producing pharmaceutical products, distribution, and specialty drugs. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Concordia International's top competitors include Cardinal Health, Xiel and CNX Therapeutics.
Concordia International has made 1 acquisition, including Amdipharm Mercury.